Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02675231
What this trial is testing

Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CancerHER-2 Positive Breast Cancer
Eli Lilly and Company 237
Testing effectiveness (Phase 2)Study completedNCT01975142
What this trial is testing

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Who this might be right for
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Institut Curie 155
Early research (Phase 1)Study completedNCT00932373
What this trial is testing

Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 54
Testing effectiveness (Phase 2)UnknownNCT04334330
What this trial is testing

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Who this might be right for
Breast CancerBrain Metastases
Sun Yat-sen University 34
Testing effectiveness (Phase 2)Study completedNCT02673398
What this trial is testing

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

Who this might be right for
HER2 Positive Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
City of Hope Medical Center 25
Not applicableStudy completedNCT03025711
What this trial is testing

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine

Who this might be right for
Breast Neoplasms
BELEN RUIZ-ANTORAN 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802876
What this trial is testing

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Who this might be right for
MSI-H Colorectal CancerMelanomaAnal Carcinoma+28 more
SOLTI Breast Cancer Research Group 184
Post-approval studies (Phase 4)Ended earlyNCT04657679
What this trial is testing

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

Who this might be right for
Breast Cancer
Georgetown University 21
Large-scale testing (Phase 3)Active Not RecruitingNCT02107703
What this trial is testing

Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 669
Early research (Phase 1)Study completedNCT02073916
What this trial is testing

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Jenny C. Chang, MD 24
Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Testing effectiveness (Phase 2)Study completedNCT00134680
What this trial is testing

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Who this might be right for
Metastatic Breast Cancer
Duke University 33
Large-scale testing (Phase 3)Looking for participantsNCT07008976
What this trial is testing

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 246
Testing effectiveness (Phase 2)Active Not RecruitingNCT03324425
What this trial is testing

Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

Who this might be right for
Breast Cancer Stage IV
Baylor Breast Care Center 5
Early research (Phase 1)Study completedNCT00807859
What this trial is testing

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsBreast Tumors+7 more
Amgen 65
Not applicableStudy completedNCT05839288
What this trial is testing

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Fudan University 161
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Not applicableWithdrawnNCT02616224
What this trial is testing

Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche
Next Page